HBM Healthcare Investments (Cayman) Ltd.

HBM Healthcare Investments (Cayman) Ltd. is a declared insider at 8 companies; the most frequent names are Nabriva Therapeutics plc, IVERIC bio, Inc. and Paratek Pharmaceuticals, Inc. We count 68 filings; the first trade dates from 21 March 2013 and the latest from 14 February 2023.

Both buying and selling appear: 4 purchases worth €19.9M, against 55 sales worth €24.0M. Sales outweigh purchases by €4.0M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2023 to date brings 1 purchase and no sales.

In size, the median ticket on the buying side is €4.3M. Ninety days after publication, 3 purchases show a median change of -11.5%, with the price up in 33% of them. They describe history only and say nothing certain about the share price ahead.

On 16 February 2023 came the latest disclosure, an open-market purchase for €4.7M in Mineralys Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.